-
Study aim
-
The effectiveness of various treatments in reducing psychosomatic symptoms in patients with gastrointestinal dysfunction type D
-
Design
-
A clinical trial with a control group, with parallel, randomized groups, on 48 patients.
-
Settings and conduct
-
The statistical population in this study was among all patients with gastrointestinal dysfunction (FGID) who had referred to Hamrah Psychological Institute from September to March.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
Patient cooperation to participate in the research, and complete the consent form,
First referral,
Minimum 9 years education,
Age 60-18 years,
Patients with gastrointestinal dysfunction according to ROME III criteria by a gastroenterologist for referral patients,
Diagnosis of gastrointestinal dysfunction (IBS), functional indigestion (FD), or both.
Do not take psychiatric drugs with the main purpose of reducing emotions (anxiety, etc.).
Exclusion criteria:
A history of substance abuse or dependence is currently on record during the four months before treatment,
Use of any type of psychiatric medication based on the record in the four months before the first treatment session,
Use of any kind of psychological and counseling services for any mental disorder I and II,
-
Intervention groups
-
Three treatment groups (integrated therapy), (acceptance and commitment therapy) and (short-term psychoanalysis) and a control group were assigned. First, Alexithymia (Toronto-20 Alexithymia Questionnaires), distress (mental distress with general health questionnaire), and assessment of psychosomatic symptoms (Takata and Sakata Psychosomatic Complaints Scale) completed, and then interventions were performed.
-
Main outcome variables
-
Anxiety; psychosomatic symptoms